txg-20220504false000177078700017707872022-05-042022-05-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 8-K
______________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 4, 2022
10x Genomics, Inc.
(Exact name of registrant as specified in its charter)
| | | | | | | | |
Delaware | 001-39035 | 45-5614458 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
6230 Stoneridge Mall Road
Pleasanton, California 94588
(925) 401-7300
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
___________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | | | |
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | | | | |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | | | | |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | | | | |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
Title of each class | | Trading Symbol | | Name of each exchange on which registered |
Class A common stock, par value $0.00001 per share | | TXG | | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 4, 2022, 10x Genomics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2022. A copy of the press release is attached hereto as Exhibit 99.1.
The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
| | | | | | | | | | | |
Exhibit No. | | Description of Exhibits | |
| | | |
| 99.1 | | | |
| 104 | | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| 10x Genomics, Inc. |
| | |
| By: | /s/ Eric S. Whitaker |
| Name: | Eric S. Whitaker |
| Title: | Chief Legal Officer |
| | |
| Date: May 4, 2022 | | |
Exhibit 99.1
10x Genomics Reports First Quarter 2022 Financial Results
Q1 2022 revenue growth of 8% over prior year
PLEASANTON, Calif. May 4, 2022 – 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the first quarter ended March 31, 2022.
Recent Highlights
•Revenue was $114.5 million for the first quarter, representing an 8% increase over the corresponding period of 2021.
•Showcased robust product roadmap at Xperience 2022 for the Chromium and Visium platforms and provided a first look into Xenium, the company's forthcoming In Situ platform.
•Launched two new products for fixed RNA profiling and nuclei isolation, designed to improve sample preparation and broaden the adoption of Chromium, the leading platform for single cell analysis.
"Our first quarter results reflect our team's continued focus on execution, as we navigated an expected slow start to the year to drive adoption of our leading single cell and spatial technologies," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We are on track to make 2022 the most exciting year of product launches in our history. We look forward to delivering on our product roadmap, building momentum throughout the year and accelerating growth into 2023 and beyond."
First Quarter 2022 Financial Results
Revenue was $114.5 million for the three months ended March 31, 2022, an 8% increase from $105.8 million for the three months ended March 31, 2021. This increase was primarily the result of increased consumables revenue driven by growth in cumulative instruments sold and increased instrument revenue driven by sales of Chromium X Series instruments.
Gross margin was 78% for the first quarter of 2022, as compared to 84% for the corresponding prior year period. The decrease in gross margin was primarily due to change in product mix, increased manufacturing and logistics costs, and higher accrued royalties.
Operating expenses were $130.8 million for the first quarter of 2022, a 32% increase from $99.0 million for the corresponding prior year period. This increase was driven by higher personnel expenses, including stock-based compensation, increased research and development expenses and increased infrastructure costs, partially offset by a decrease in outside legal expenses.
Operating loss was $41.7 million for the first quarter of 2022, as compared to $10.2 million for the corresponding prior year period. Operating loss includes $26.0 million of stock-based compensation for the first quarter of 2022, as compared to $16.2 million for the corresponding prior year period.
Net loss was $42.4 million for the first quarter of 2022, as compared to a net loss of $11.6 million for the corresponding prior year period.
Cash and cash equivalents and marketable securities were $539.3 million as of March 31, 2022.
2022 Financial Guidance
10x Genomics is maintaining its full year 2022 revenue guidance of $600 million to $630 million, representing 22% to 28% growth over full year 2021 revenue.
Webcast and Conference Call Information
10x Genomics will host a conference call to discuss the first quarter 2022 financial results, business developments and outlook after market close on Wednesday, May 4, 2022 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference
call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay at least 45 days after the event.
About 10x Genomics
10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2020 based on publications and all of the top 20 global pharmaceutical companies by 2020 research and development spend and have been cited in over 3,500 research papers on discoveries ranging from oncology to immunology and neuroscience. Our patent portfolio comprises more than 1,350 issued patents and patent applications.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.’s expectations regarding our business operations, financial performance and results of operations, including our expectations regarding revenue and guidance, as well as our ability to meet our anticipated cash needs for the foreseeable future. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. The material risks and uncertainties that could affect 10x Genomics, Inc.’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Although 10x Genomics, Inc. believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. These forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments 10x Genomics may make. Further, as the COVID-19 pandemic is continuously evolving, such forward-looking statements may not accurately or fully reflect the potential impact that the COVID-19 pandemic may have on the business, financial condition, results of operations and cash flows of 10x Genomics, Inc. The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics, Inc.’s views as of any date subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
Contacts
10x Genomics, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share data)
| | | | | | | | | | | | | | | |
| Three Months Ended
March 31, | | |
| 2022 | | 2021 | | | | |
| Revenue | $ | 114,496 | | | $ | 105,821 | | | | | |
| Cost of revenue (1) | 25,478 | | | 17,060 | | | | | |
| Gross profit | 89,018 | | | 88,761 | | | | | |
| Operating expenses: | | | | | | | |
| Research and development (1) | 64,078 | | | 41,883 | | | | | |
| | | | | | | |
| Selling, general and administrative (1) | 66,675 | | | 56,904 | | | | | |
| Accrued contingent liabilities | — | | | 190 | | | | | |
| Total operating expenses | 130,753 | | | 98,977 | | | | | |
| Loss from operations | (41,735) | | | (10,216) | | | | | |
| Other income (expense): | | | | | | | |
| Interest income | 569 | | | 50 | | | | | |
| Interest expense | (128) | | | (221) | | | | | |
| Other expense, net | (400) | | | (729) | | | | | |
| | | | | | | |
| Total other income (expense) | 41 | | | (900) | | | | | |
| Loss before provision for income taxes | (41,694) | | | (11,116) | | | | | |
| Provision for income taxes | 719 | | | 435 | | | | | |
| Net loss | $ | (42,413) | | | $ | (11,551) | | | | | |
| | | | | | | |
| Net loss per share, basic and diluted | $ | (0.38) | | | $ | (0.11) | | | | | |
| Weighted-average shares of common stock used in computing net loss per share, basic and diluted | 112,966,196 | | | 108,714,027 | | | | | |
(1)Includes stock-based compensation expense as follows:
| | | | | | | | | | | | | | | |
| Three Months Ended
March 31, | | |
(in thousands) | 2022 | | 2021 | | | | |
| Cost of revenue | $ | 1,014 | | | $ | 464 | | | | | |
| Research and development | 11,291 | | | 6,796 | | | | | |
| Selling, general and administrative | 13,742 | | | 8,916 | | | | | |
| Total stock-based compensation expense | $ | 26,047 | | | $ | 16,176 | | | | | |
10x Genomics, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands)
| | | | | | | | | | | |
| March 31,
2022 | | December 31,
2021 |
| Assets | | | |
| Current assets: | | | |
| Cash and cash equivalents | $ | 312,487 | | | $ | 587,447 | |
| Marketable securities | 226,836 | | | — | |
| Restricted cash | 27 | | | 1,028 | |
| Accounts receivable, net | 76,526 | | | 85,254 | |
| Inventory | 63,697 | | | 59,966 | |
| Prepaid expenses and other current assets | 17,762 | | | 13,896 | |
| Total current assets | 697,335 | | | 747,591 | |
| Property and equipment, net | 190,200 | | | 169,492 | |
| Restricted cash | 7,598 | | | 7,598 | |
| Operating lease right-of-use assets | 75,680 | | | 60,918 | |
| Goodwill | 4,511 | | | 4,511 | |
| Intangible assets, net | 24,764 | | | 25,397 | |
| Other noncurrent assets | 3,163 | | | 3,319 | |
| Total assets | $ | 1,003,251 | | | $ | 1,018,826 | |
| Liabilities and stockholders’ equity | | | |
| Current liabilities: | | | |
| Accounts payable | $ | 18,956 | | | $ | 17,351 | |
| Accrued compensation and related benefits | 18,324 | | | 31,626 | |
| Accrued expenses and other current liabilities | 44,095 | | | 50,909 | |
| | | |
| Deferred revenue | 5,434 | | | 5,340 | |
| Operating lease liabilities | 7,637 | | | 5,131 | |
| | | |
| Total current liabilities | 94,446 | | | 110,357 | |
| | | |
| | | |
| Accrued license fee, noncurrent | — | | | 5,814 | |
| | | |
| Operating lease liabilities, noncurrent | 93,538 | | | 76,847 | |
| Other noncurrent liabilities | 8,582 | | | 8,240 | |
| Total liabilities | 196,566 | | | 201,258 | |
| Commitments and contingencies | | | |
| Stockholders’ equity: | | | |
| Preferred stock | — | | | — | |
| Common stock | 2 | | | 2 | |
| Additional paid-in capital | 1,714,860 | | | 1,680,865 | |
| Accumulated deficit | (905,734) | | | (863,321) | |
| Accumulated other comprehensive income (loss) | (2,443) | | | 22 | |
| Total stockholders’ equity | 806,685 | | | 817,568 | |
| Total liabilities and stockholders’ equity | $ | 1,003,251 | | | $ | 1,018,826 | |
